Top Page
Zai Lab Ltd
(Frankfurt:9688)
Zai Lab Ltd (9688) vs. iShares MSCI Hong Kong ETF (EWH)
Zai Lab Ltd Business Overview & Revenue Model
Zai Lab Ltd Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 398.99M | 266.72M | 215.04M | 144.31M | 48.96M |
| Gross Profit | 251.13M | 170.90M | 141.02M | 92.07M | 32.22M |
| EBITDA | -242.99M | -365.11M | -384.66M | -689.46M | -262.96M |
| Net Income | -257.10M | -334.62M | -481.99M | -692.44M | -298.16M |
Balance Sheet | |||||
| Total Assets | 1.19B | 1.04B | 1.22B | 1.61B | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 779.67M | 806.45M | 1.01B | 1.41B | 1.19B |
| Total Debt | 153.47M | 15.15M | 20.39M | 15.54M | 18.60M |
| Total Liabilities | 344.86M | 240.18M | 174.54M | 230.00M | 128.29M |
| Stockholders Equity | 840.90M | 796.12M | 1.05B | 1.38B | 1.17B |
Cash Flow | |||||
| Free Cash Flow | -276.39M | -206.67M | -392.63M | -568.18M | -226.72M |
| Operating Cash Flow | -214.87M | -198.18M | -367.64M | -549.23M | -216.06M |
| Investing Cash Flow | -375.19M | -10.78M | 420.02M | 249.96M | -554.83M |
| Financing Cash Flow | 349.89M | -6.43M | -1.73M | 820.20M | 1.13B |
Zai Lab Ltd Technical Analysis
Zai Lab Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$32.42B | 38.80 | 31.65% | ― | 4.23% | 47.71% | |
64 Neutral | HK$7.82B | 44.24 | 9.52% | ― | 185.36% | ― | |
61 Neutral | HK$40.71B | ― | -56.68% | ― | 52.25% | 11.46% | |
60 Neutral | HK$17.01B | 5.47 | -7.44% | 3.80% | 11.55% | -28.15% | |
59 Neutral | HK$9.22B | ― | -51.40% | ― | 58.75% | -1310.16% | |
59 Neutral | HK$38.89B | ― | -19.78% | ― | 25.96% | 39.58% | |
51 Neutral | HK$30.15B | ― | -32.29% | ― | 43.13% | 28.93% |
Zai Lab Ltd Corporate Events
Zai Lab Ltd has announced the grant of share options, restricted share units, and performance share units under its 2024 Equity Incentive Plan. This move, which includes significant allocations to key personnel such as Dr. Samantha Du, aims to align the interests of employees with the company’s growth objectives and maintain competitive compensation practices. The grants are structured without performance targets or clawback mechanisms, reflecting the company’s customary practices and market competitiveness.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited has announced a change in its head office and principal place of business in the People’s Republic of China. Effective July 1, 2025, the company’s new location will be in Pudong, Shanghai. This move may indicate strategic positioning within the region, potentially impacting its operational efficiency and market presence in China.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited announced the resignation of Ms. Nelly Au-Yeung as joint company secretary and authorized representative, effective June 27, 2025. Mr. Frazor Titus Edmondson III will assume the role of sole company secretary and authorized representative, ensuring continuity in corporate governance. The board expressed gratitude to Ms. Au-Yeung for her contributions.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Ltd announced the granting of share options and restricted share units under its 2024 Equity Incentive Plan. On June 3, 2025, the company granted options to subscribe for 2,500 American Depositary Shares (ADSs) to one employee and restricted share units covering 4,104 ADSs to three employees. This move is part of Zai Lab’s strategy to align employee incentives with company performance, although the grants do not include performance targets or clawback mechanisms. The compensation committee believes this approach is market competitive and consistent with the company’s customary practices.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Ltd announced the grant of 9,800 Restricted Share Units to two employees under its 2024 Equity Incentive Plan. This initiative aims to recognize and reward the employees’ contributions and incentivize their continued efforts towards the company’s success. The grants, which have no performance targets or clawback mechanisms, are seen as market competitive and aligned with the company’s practices, potentially enhancing employee retention and motivation.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited reported a 22% year-over-year increase in total revenues for the first quarter of 2025, reaching $106.5 million, and is on track to achieve profitability by the fourth quarter of 2025. The company is advancing its oncology pipeline with promising data presentations and is poised for growth with a strong cash position and expanding global portfolio, aiming to drive long-term shareholder value.
Zai Lab Limited announced the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, with the U.S. Securities and Exchange Commission. This filing is part of the company’s regulatory compliance and provides stakeholders with updated financial and operational information, potentially impacting its market positioning and investor relations.
Zai Lab Ltd has announced its 2025 annual general meeting of shareholders, scheduled for June 18, 2025, in Shanghai and virtually. The meeting will address several key resolutions, including the re-election of directors, the appointment of KPMG as auditors, and the approval of executive compensation and share issuance mandates, which are crucial for the company’s governance and strategic planning.
Zai Lab Limited has announced that its Audit Committee will review and approve the company’s unaudited quarterly results for the first quarter of 2025 on May 8, 2025. The results, prepared in accordance with U.S. GAAP and SEC rules, will be published on the same day. Following the release, the company will host a live earnings call and webcast to discuss the results, providing an opportunity for stakeholders to engage with the company’s management.
Zai Lab Limited has filed preliminary proxy materials with the U.S. Securities and Exchange Commission for its 2025 annual general meeting. The agenda includes the re-election of directors, approval of auditor appointments, and authorization for the board to manage share allotments and repurchases. This filing is a regulatory step towards the annual meeting, reflecting Zai Lab’s commitment to corporate governance and shareholder engagement.